ArticleMikrochimica acta2026
Dual-cytokine profiling of inflammatory states using a rapid electroanalytical device as a point-of-care sensor platform.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dynamic mechanism of inflammation plays a pivotal role in the pathogenesis of many acute and chronic disease states, with interleukin-18 (IL-18) and interleukin-10 (IL-10) as important markers representing pro-inflammatory and anti-inflammatory responses, respectively. An imbalance in the levels of these cytokines can worsen disease severity and patient outcome, highlighting the need for tools that simultaneously detect and quantify levels for diagnostic purposes. This study uses the READ (Rapid Electrochemical Analysis Device) platform, an innovative biosensor technology, utilizing the electrochemical impedance spectroscopy (EIS) technique, which is equipped to quantify IL-18 and IL-10 levels directly in human blood samples. The READ platform offers sensitive, label-free detection of inflammatory markers with a rapid processing time (< 10 min) and requires minimal sample volume (≤ 160 µl). The device exhibited a robust analytical performance, with a strong dose-response linearity (R² = 0.98–0.99), consistent recovery (80–120%), and minimal cross-reactivity across cytokines (IL-18 and IL-10) and across matrices (K2-EDTA whole blood and plasma). The portable, user-friendly approach to the READ platform bridges the gap between tedious laboratory processing and clinical-level field deployment, thus paving the way for personalized inflammatory disease management. This work highlights a transformative approach to cytokine monitoring, allowing for early intervention and improved therapeutic outcomes for patients fighting inflammatory states.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.